January was a rough month for many pharma employees in California, as several companies pulled the trigger on layoffs, or announced coming layoffs that will affect hundreds of employees.
South San Francisco mainstay Genentech, a Roche company, announced additional cuts. On Jan. 24, the company filed a notice showing 67 layoffs would begin effective March 29. The company noted in the WARN notice that the layoffs were permanent. Nadine Pinell, Genentech’s principal manager of corporate relations said the layoffs, which she described as a difficult decision, will cover multiple departments at the company.
In an email to BioSpace, Pinell said the company has been evaluating its operations to ensure it remains well-positioned to meet the needs of patients and deliver on its pipeline.
“As a result of this process, we have made the difficult decision to eliminate some positions,” Pinell said. “At Genentech, we pursue groundbreaking science to develop breakthrough medicines for people with serious diseases. The success of our business depends on our ability to respond to change, appropriately allocate resources, and manage our operations efficiently.”
Pinell added that the company appreciates the contributions of its employees who have been impacted by the job cuts. She said Genentech will support them through the transition with financial benefits, extended healthcare coverage, and career coaching.
The layoffs set for March follow 83 job cuts the company made late in 2018. At the time of those cuts, Pinell made a similar comment to BioSpace regarding the layoffs. In August 2018, the company also announced 223 job cuts in South San Francisco.
Also making cuts is Merck Sharp & Dohme. According to a WARN notification issued Jan. 18, the company will cut 20 employees in Palo Alto as part of a closure.
For 2019, layoffs in California began in January with Aduro Biotech, which announced it was cutting 37 percent of its staff as part of a corporate restructuring. The company said it will institute a “strategic reset” to focus on its core strengths of the discovery and development of novel product candidates in the stimulator of interferon genes (STING) and a proliferation-inducing ligand (APRIL) pathways. The money it saves from cutting a third of its employees will be used to support development of the company’s lead programs, Aduro said in January.
Aduro isn’t the only California company to make job cuts. Pharma giant Pfizer will execute the shift of 100 jobs from South San Francisco to La Jolla. First announced in December, Pfizer said that the plan to shift the jobs from the Bay Area to the San Diego area was part of an effort to “simplify the organizational structure and footprint of our oncology research unit.” By consolidating its oncology programs between the two sites, Pfizer said it will be “better positioned” to take advantage of “the critical mass needed to more rapidly deliver innovative targeted and immunotherapeutic medicines to patients in need.”
Also making cuts this year is Theravance Biopharma. The Ireland based company announced plans to cut one employee in the Los Angeles area and 49 in South San Francisco. Those cuts are expected to go into effect on March 8, according to the WARN notice. Theravance announced its workforce reduction in January as part of an effort to align with its focus on continued execution of key strategic programs. The employees begin cut by Theravance primarily focused on early research or the infrastructure in support of Vibativ (telavancin). Vibativ is a marketed antibiotic recently sold by the company to Cumberland Pharmaceuticals, Inc. Cumberland acquired the drug for $25 million in November 2018.
位于旧金山的罗氏（Roche）公司基因泰克（Genentech）宣布进一步裁员。1月24日，该公司提交了一份公告，显示67人的裁员将于3月29日开始生效。该公司在 WARN 通知中指出，裁员是永久性的。基因泰克（Genentech）负责公司关系的首席经理 Nadine Pinell 表示，裁员将涉及公司多个部门，她认为这是一个艰难的决定。
Pinell 在给 BioSpace 的一封电子邮件中表示，该公司一直在评估其运营情况，以确保其保持良好的定位，以满足患者的需求并交付其管道。
“由于这个过程，我们做出了艰难的决定，取消了一些职位，” Pinell 说。“在基因泰克（Genentech）技术公司，我们追求突破性科学，为患有严重疾病的人开发突破性药物。我们的业务能否成功，取决于我们是否有能力应对变化、适当分配资源和高效管理运营。”
今年3月裁员之前，该公司在2018年末裁员83人。在裁员之时， Pinell 就裁员问题向 BioSpace 发表了类似的评论。2018年8月，公司还宣布在旧金山南部裁员223人。
同样裁员的还有默克（Merck） Sharp & Dohme 。根据 WARN 1月18日发布的一份通知，作为关闭的一部分，该公司将裁减帕洛阿尔托的20名员工。
2019年，加州的裁员始于1月份 Aduro Biotech 公司，该公司宣布裁员37%，作为公司重组的一部分。该公司表示，将进行一次“战略重组”，重点关注其在干扰素基因刺激器（ STING ）和诱导增殖配体（ APRIL ）路径中发现和开发新产品候选物的核心优势。今年1月， Aduro 表示，从裁员三分之一中节省下来的资金将用于支持公司领导计划的发展。
今年还削减了 Theraviance 生物制药公司。这家总部位于爱尔兰的公司宣布，计划在洛杉矶地区裁员1人，在旧金山南部裁员49人。根据 WARN 的通知，这些裁员预计将于3月8日生效。该公司宣布将在1月份裁员，以配合其继续执行关键战略计划的努力。该公司的员工开始裁员，主要集中在早期研究或支持 Vibativ （ telaviance ）的基础设施。Vibativ 是公司最近向 Cumberland Pharmaceuticals , Inc .销售的一种已上市抗生素， Cumberland 于2018年11月以2,500万美元收购了该药物。